Where Better-Absorbed
Creatine Began
The CGG Amino-Bridge™ delivery approach traces back to early research originating at KAIST: can pairing creatine with glycine and glutamine improve how much the body actually absorbs and retains?
A Research Question That
Changed Everything
Creatine is one of the most studied compounds in sports and cellular-energy science. Its role in regenerating ATP — the energy currency that powers muscle and brain cells — is well established. But a practical limitation remained: a meaningful portion of standard creatine monohydrate is poorly retained and excreted rather than absorbed.
Early research originating at KAIST explored a different question: could pairing creatine with specific amino acids improve how much the body actually absorbs and retains? This preclinical work is the origin of the delivery approach behind CGG Amino-Bridge™.
"The goal was a better-delivered creatine — improving absorption and retention so more of each dose is usable, rather than simply taking larger amounts."
The approach that followed became CGG Amino-Bridge™ — pairing creatine monohydrate with glycine and glutamine in a configuration intended to support absorption, retention, and overall bioavailability.
Science & Technology
Daejeon, South Korea
Standard Creatine Is
Often Poorly Retained
Creatine works — but absorption and retention vary. A meaningful share of a standard dose can be excreted rather than taken up and held by the body, which is why intake and retention don't always match.
CGG Amino-Bridge™:
Engineering the Shuttle
The amino acids paired with creatine — glycine and glutamine — are themselves well absorbed and metabolically active. The idea was to use a creatine + amino acid configuration to support better absorption and retention.
By pairing creatine monohydrate with glycine and glutamine in a precise configuration, the CGG Amino-Bridge™ approach is intended to help more of each dose be absorbed and retained rather than excreted — improving overall bioavailability.
The aim is straightforward: get more usable creatine from the same dose, supporting the cellular energy (ATP) that powers both muscle and brain — without relying on a larger dose or a loading phase.
From Early Research
to an Independent Pilot
The CGG Amino-Bridge™ approach moved from early KAIST-origin research toward an independent human pilot study. The supporting human data so far is preliminary, and larger studies are needed.
KAIST-Origin Research.
Independent EIMEC Pilot.
The delivery approach behind CREGEN traces to early research originating at KAIST, and has been examined in a small independent pilot at EIMEC in Barcelona. The human data so far is preliminary.
- ✓ Origin of early research into creatine absorption and retention
- ✓ Explored pairing creatine with glycine and glutamine
- ✓ Foundation for the CGG Amino-Bridge™ delivery approach
- ✓ Early / preclinical stage — preliminary research
- ✓ Focused on better bioavailability, not a higher dose
- ✓ Independent controlled human pilot (small, preliminary)
- ✓ ~56% lower urinary creatine loss vs competitor (p<0.05)
- ✓ Directional trends toward higher serum and plasma creatine
- ✓ No affiliation with the brand — fully independent
- ✓ Exploratory results — larger studies are needed
The independent nature of the EIMEC pilot matters: it was conducted with no affiliation to the brand. That said, the human evidence to date is a single small pilot study and is preliminary. We describe it as exploratory, and larger, controlled studies are needed to confirm these early findings.
KAIST-Origin Research · Independent EIMEC Pilot
Better-Delivered Creatine.
For Brain and Body.
CREGEN is formulated with the CGG Amino-Bridge™ delivery approach — pairing creatine with glycine and glutamine to support absorption and retention. Korean-origin research. An independent European pilot. Made in the USA.